215 related articles for article (PubMed ID: 31619095)
1. A structure-based approach towards the identification of novel antichagasic compounds:
Llanos MA; Sbaraglini ML; Villalba ML; Ruiz MD; Carrillo C; Alba Soto C; Talevi A; Angeli A; Parkkila S; Supuran CT; Gavernet L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):21-30. PubMed ID: 31619095
[No Abstract] [Full Text] [Related]
2. Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
Pan P; Vermelho AB; Capaci Rodrigues G; Scozzafava A; Tolvanen ME; Parkkila S; Capasso C; Supuran CT
J Med Chem; 2013 Feb; 56(4):1761-71. PubMed ID: 23391336
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of carbonic anhydrase from Trypanosoma cruzi for the management of Chagas disease: an underexplored therapeutic opportunity.
Supuran CT
Future Med Chem; 2016; 8(3):311-24. PubMed ID: 26898220
[TBL] [Abstract][Full Text] [Related]
4. Appraisal of anti-protozoan activity of nitroaromatic benzenesulfonamides inhibiting carbonic anhydrases from
Nocentini A; Osman SM; Almeida IA; Cardoso V; Alasmary FAS; AlOthman Z; Vermelho AB; Gratteri P; Supuran CT
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1164-1171. PubMed ID: 31219348
[TBL] [Abstract][Full Text] [Related]
5. Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles.
Nocentini A; Cadoni R; Dumy P; Supuran CT; Winum JY
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):286-289. PubMed ID: 29278948
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel drugs for Chagas disease: is carbonic anhydrase a target for antiprotozoal drugs?
Beatriz Vermelho A; Rodrigues GC; Nocentini A; Mansoldo FRP; Supuran CT
Expert Opin Drug Discov; 2022 Oct; 17(10):1147-1158. PubMed ID: 36039500
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease.
Rodrigues GC; Feijó DF; Bozza MT; Pan P; Vullo D; Parkkila S; Supuran CT; Capasso C; Aguiar AP; Vermelho AB
J Med Chem; 2014 Jan; 57(2):298-308. PubMed ID: 24299463
[TBL] [Abstract][Full Text] [Related]
8. Nanoemulsions of sulfonamide carbonic anhydrase inhibitors strongly inhibit the growth of Trypanosoma cruzi.
Vermelho AB; da Silva Cardoso V; Ricci Junior E; Dos Santos EP; Supuran CT
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):139-146. PubMed ID: 29192555
[TBL] [Abstract][Full Text] [Related]
9. A class of sulfonamides with strong inhibitory action against the α-carbonic anhydrase from Trypanosoma cruzi.
Güzel-Akdemir Ö; Akdemir A; Pan P; Vermelho AB; Parkkila S; Scozzafava A; Capasso C; Supuran CT
J Med Chem; 2013 Jul; 56(14):5773-81. PubMed ID: 23815159
[TBL] [Abstract][Full Text] [Related]
10. Anion inhibition studies of the α-carbonic anhydrase from the protozoan pathogen Trypanosoma cruzi, the causative agent of Chagas disease.
Pan P; Vermelho AB; Scozzafava A; Parkkila S; Capasso C; Supuran CT
Bioorg Med Chem; 2013 Aug; 21(15):4472-6. PubMed ID: 23790722
[TBL] [Abstract][Full Text] [Related]
11. A new class of quinazoline-sulfonamides acting as efficient inhibitors against the α-carbonic anhydrase from Trypanosoma cruzi.
Alafeefy AM; Ceruso M; Al-Jaber NA; Parkkila S; Vermelho AB; Supuran CT
J Enzyme Inhib Med Chem; 2015; 30(4):581-5. PubMed ID: 25373503
[TBL] [Abstract][Full Text] [Related]
12. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
Monteiro ME; Lechuga G; Lara LS; Souto BA; Viganó MG; Bourguignon SC; Calvet CM; Oliveira FOR; Alves CR; Souza-Silva F; Santos MS; Pereira MCS
Eur J Med Chem; 2019 Nov; 182():111610. PubMed ID: 31434040
[TBL] [Abstract][Full Text] [Related]
14. Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
Paucar R; Martín-Escolano R; Moreno-Viguri E; Azqueta A; Cirauqui N; Marín C; Sánchez-Moreno M; Pérez-Silanes S
Bioorg Med Chem; 2019 Sep; 27(17):3902-3917. PubMed ID: 31345745
[TBL] [Abstract][Full Text] [Related]
15. Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship.
Gao R; Liao S; Zhang C; Zhu W; Wang L; Huang J; Zhao Z; Li H; Qian X; Xu Y
Eur J Med Chem; 2013 Apr; 62():597-604. PubMed ID: 23429054
[TBL] [Abstract][Full Text] [Related]
16. Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents.
Chennamaneni NK; Arif J; Buckner FS; Gelb MH
Bioorg Med Chem Lett; 2009 Dec; 19(23):6582-4. PubMed ID: 19875282
[TBL] [Abstract][Full Text] [Related]
17. Discovery of New Potential Anti-Infective Compounds Based on Carbonic Anhydrase Inhibitors by Rational Target-Focused Repurposing Approaches.
Annunziato G; Angeli A; D'Alba F; Bruno A; Pieroni M; Vullo D; De Luca V; Capasso C; Supuran CT; Costantino G
ChemMedChem; 2016 Sep; 11(17):1904-14. PubMed ID: 27304878
[TBL] [Abstract][Full Text] [Related]
18. In Silico Studies Designed to Select Sesquiterpene Lactones with Potential Antichagasic Activity from an In-House Asteraceae Database.
Acevedo CH; Scotti L; Scotti MT
ChemMedChem; 2018 Mar; 13(6):634-645. PubMed ID: 29323468
[TBL] [Abstract][Full Text] [Related]
19. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, antioxidant and antichagasic properties of a selected series of hydroxy-3-arylcoumarins.
Robledo-O'Ryan N; Matos MJ; Vazquez-Rodriguez S; Santana L; Uriarte E; Moncada-Basualto M; Mura F; Lapier M; Maya JD; Olea-Azar C
Bioorg Med Chem; 2017 Jan; 25(2):621-632. PubMed ID: 27908757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
